-- 
AMG, CFE, CSM, Telenet, ThromboGenics: Benelux Equity Preview

-- B y   J o h n   M a r t e n s   a n d   F r e d   P a l s
-- 
2011-08-10T04:00:04Z

-- http://www.bloomberg.com/news/2011-08-09/amg-cfe-csm-telenet-thrombogenics-benelux-equity-preview.html
The following companies may have
unusual price changes in Benelux markets. Stock symbols are in
parentheses, and prices are from the previous close.  The  AEX-Index (AEX)  in Amsterdam increased 1.3 percent to 287.05.
 Belgium ’s Bel20 Index rose 2.8 percent to 2,154.72. Luxembourg’s
LuxX Index lost 0.4 percent to 1,151.01.  Dutch stocks:  AMG Advanced Metallurgical Group NV (AMG)  : The maker of
vacuum furnaces and specialty alloys based on aluminum and
titanium is scheduled to report second-quarter earnings. AMG
shares soared 9.2 percent to 9.35 euros.  CSM (CSM)  NV: The world’s biggest maker of bakery
ingredients may say first-half net income dropped to 31.1
million euros ($44.2 million), according to the average of three
analyst estimates compiled by Bloomberg, from 54.2 million euros
a year earlier. CSM shares advanced 2.8 percent to 15.99 euros.  Belgian stocks:  Ackermans & van Haaren NV (ACKB)  , Cie. d’Entreprises CFE
SA (CFEB BB): Dredging Environmental & Marine Engineering NV,
the dredging company co-owned by Ackermans and CFE, said its
Australian joint venture with Van Oord Groep NV won a contract
valued at A$120 million ($122 million) for the development of
the Gladstone liquefied-natural-gas project. Ackermans shares
gained 4 percent to 53.09 euros. CFE shares climbed 5.8 percent
to 38.45 euros.  Telenet Group Holding NV (TNET)  : The Belgian cable
operator controlled by Liberty Global Inc. said it initiated a
stock buyback program and will give weekly updates of the shares
bought back to cover stock option awards to management. Telenet
shares increased 7.3 percent to 26.39 euros.  ThromboGenics NV (THR)  : The Belgian developer of the
Ocriplasmin eye-disease treatment said it plans to seek European
regulatory approval for the experimental drug in the next two
months, with a U.S. filing scheduled before year-end. The shares
surged 9.7 percent to 14.53 euros.  To contact the reporters on this story:
John Martens in Brussels at 
 jmartens1@bloomberg.net ;
Fred Pals in Amsterdam at 
 fpals@bloomberg.net   To contact the editor responsible for this story:
Angela Cullen at 
 acullen8@bloomberg.net  